

2018-2019

ANNOUNCEMENT

REGARDING

FINANCIAL RESULTS

FOR THE HALF YEAR

ENDED MARCH 31, 2018

AND THE YEAR

ENDED MARCH 31, 2018

AND THE YEAR

ENDED MARCH 31, 2018

Under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing here with Audited Financial Results of the Company for the Half Year and Year ended March 31, 2018, along with the Statement of Impact of Audit qualifications for the Standalone Financial Results duly approved by Board of Directors of the Company at its meeting held on 28<sup>th</sup> May, 2018.

The meeting was held on 28<sup>th</sup> May, 2018.

For and on behalf of the Board of Directors

Signature of

Chairman

Dr. Anil Kumar Singh



Dr. Anil Kumar Singh

Chairman



## INDEPENDENT AUDITOR'S REPORT

To,

The Board of Directors of

S.J. Bio-Tech Limited,

"Shilparth Bhavan", Opp. Mahesh Complex, Madhav Road,

Surat - 392 004.

- 1 We have audited the Half Yearly Financial Results of S.J. Bio-Tech Limited (The Company) formerly known as S.J. Bio-Tech Private Limited for the Half Year ended on 31.03.2018 and the year to date results for the period 01.04.2017 to 31.03.2018, mentioned hereinafter, having submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These Half Yearly Financial Results as well as the year to date financial results have been prepared on the basis of the Half Yearly & Annual Financial Statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such Half Yearly & Annual Financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Half Yearly & Annual Financial Reporting, prescribed under section 133 of the Companies Act, 2013 and other financial reporting standards applicable to the business of the company and the Indian Accounting Standards applicable in India, as applicable and other accounting principles generally accepted in India.

- 2 The conclusion for audit in accordance with the auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes evaluating, on a test basis, evidence supporting the company's accounting policies, financial statements and internal controls, assessing accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

## 3 Basis for Qualified Opinion

- (i) Following matters conditions indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern and therefore, it may be unable to realize its assets and discharge its liabilities in the normal course of business. The financial statements have been prepared on the basis of the facts that, as at 31.03.2018, the shareholders financial statements of the Company have been prepared on a going concern basis.

We draw attention to the shareholders financial statements, which indicate that -

- The Company has reported a net loss of Rs. 26.38 Crores during the year ended 31st March, 2018 and the 50 percent dividend may current needs sanctioned by the AGM.

- The Company's management does not intend to withdraw from the fully audited.

- The Company's financing arrangements expired and the amount outstanding of Rs. 31.48 Crores was payable on March 31, 2018. The Company has been unable to re-negotiate or obtain replacement financing and has reported classified by bank as Non Performing Assets.





Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005 (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111  
E-mail : info@rjbiotech.com www.rjbiotech.com CIN No. : L24234MH2005PLC158420.

Audited Statement of Assets and Liabilities as on 31<sup>st</sup> March, 2018

(Rs. in Lakhs)

Particulars	As on 31-03-2018	As on 31-03-2017
<b>I] EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	946.76	946.76
(b) Reserves & Surplus	(1,928.12)	148.54
(c) Money received against share warrants	-	-
<b>Total Shareholders Fund</b>	<b>(981.36)</b>	<b>1,095.30</b>
(2) Share Application money pending allotment	-	-
(3) Deferred Government Grants	-	-
(4) Minority Interest	-	-
<b>(5) Non-Current Liabilities</b>		
(a) Long-term borrowings	525.71	146.50
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long term Liabilities	59.60	84.71
(d) Long-term Provisions	-	-
<b>Total Non-Current Liabilities</b>	<b>585.31</b>	<b>231.21</b>
<b>(6) Current Liabilities</b>		
(a) Short-Term Borrowings	3,136.41	2,756.67
(b) Trade Payables		
i) Micro enterprises and small enterprises	-	-
ii) Other than micro enterprises and small enterprises	335.08	186.69
(c) Other Current Liabilities	360.54	422.77
(d) Short-Term Provisions	71.65	60.52
<b>Total Current Liabilities</b>	<b>3,903.68</b>	<b>3,426.65</b>
<b>TOTAL</b>	<b>3,507.62</b>	<b>4,753.15</b>
<b>II] ASSETS</b>		
<b>(1) Non Current Assets</b>		
(a) Fixed Assets		
(i) Tangible Assets	183.94	195.23
(ii) Intangible Assets	0.22	0.05
(iii) Capital Work-in-progress	-	-
(iv) Intangible Assets under Development	-	-
<b>Total Fixed Asset</b>	<b>184.16</b>	<b>195.28</b>



*Signature*

**CIN No. : L24234MH2005PLC158420.**

**Audited Financial Results for the period on 2014**

**Registered Office :** Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111  
E-mail : info@rjbiotech.com www.rjbiotech.com **CIN No. :** L24234MH2005PLC158420.

12.	Net Profit/(loss) from discontinuing operations(after tax)(10-11)	-	-	-	-	-	-
13.	Profit/(Loss) for the period before minority interest	(1,741.24)	(335.42)	(1,281.59)	(2,076.66)	(1,501.70)	(1,501.70)
14.	Share of profit/(loss) of associates	-	-	-	-	-	-
15.	Minority Interest	-	-	-	-	-	-
16.	Net profit/(loss) for the period	(1,741.24)	(335.42)	(1,281.59)	(2,076.66)	(1,501.70)	(1,501.70)
17.	Details of Equity share Capital						
	Paid up equity share capital	946.76	946.76	946.76	946.76	946.76	946.76
	Face value of Equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
18.	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	(1,928.12)	(186.88)	847.57	(1,928.12)	148.54	148.54
19i	(a) Basic & diluted EPS before	(36.88)	(3.54)	(27.15)	(21.93)	(15.86)	(15.86)

Net Profit/(loss) from discontinuing operations(after tax)(10-11)

Profit/(Loss) for the period before minority interest

Share of profit/(loss) of associates

Minority Interest

Net profit/(loss) for the period

Details of Equity share Capital

Paid up equity share capital

Face value of Equity share capital

Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year

(a) Basic & diluted EPS before



For and on behalf of Board of Directors  
Signature  
Date: 15/05/2017  
Place: Aurangabad

## ANNEXURE 1

**Statement on Impact of Audit Qualifications (for audit report with Qualified opinion)**

11/20/2011 11:20:00 AM

It is well-known that the act of commissioning a building is a complex and multi-faceted process that often involves a number of different stakeholders. The Commissioning process is a critical part of the building process, and it is essential to ensure that the building is designed and constructed to meet the needs of the building owner and the building users. The Commissioning process is a multi-stage process that involves a number of different stakeholders, including the building owner, the building user, the building designer, the building contractor, and the building commissioning agent. The Commissioning process is a critical part of the building process, and it is essential to ensure that the building is designed and constructed to meet the needs of the building owner and the building users. The Commissioning process is a multi-stage process that involves a number of different stakeholders, including the building owner, the building user, the building designer, the building contractor, and the building commissioning agent.

We know and understand that the standards for the 21st century are different from the standards of the 20th century.

- [illegible]

[illegible][illegible]


10-10-68





iii. Auditors' Comments on (i) or (ii) above: we have reviewed the above Managements response, Our opinion stated in point No.( i, ii, iii) in Auditors Qualification remains unchanged.

**Signatories:**

**For R J Biotech Limited**

  
**Raghavendra Joshi**  
Chairman




  
**Aarti Pawar**  
Chief Financial Officer

**For Ashok Patil & Associates**  
Chartered Accountants  
Firm Reg. No. 122045W

  
**Ashok P. Patil**  
Partner  
M. No. 34423



  
**Anil Vasant Dharmadhikari**  
Audit Committee Chairman

**Place: Aurangabad**

**Date: 28/05/2018**